Key result
Plozasiran achieves ~39-point higher rate of target triglyceride reduction than olezarsen in simulated FCS.
Why the study?
Familial chylomicronemia syndrome causes severe hypertriglyceridemia and increases acute pancreatitis risk, motivating an indirect comparison of the effectiveness of two novel triglyceride-lowering APOC3 RNA inhibitors in these patients.
Does plozasiran increase the proportion of patients achieving serum triglyceride levels <500 mg/dl compared with olezarsen in familial chylomicronemia syndrome?
Does plozasiran increase the proportion of patients achieving serum triglyceride levels <500 mg/dl compared with olezarsen in familial chylomicronemia syndrome?
Answers are grounded in this paper and cite their sources.
An individual patient microsimulation model indirectly comparing two APOC3 RNA inhibitors suggests plozasiran is more likely than olezarsen to reduce serum triglycerides below 500 mg/dl at 10 months in patients with familial chylomicronemia syndrome.
Aim: Familial chylomicronemia syndrome (FCS) is a rare disorder caused by severe hypertriglyceridemia which increases risk for life-threatening acute pancreatitis (AP). The aim of this study was to indirectly compare the effectiveness of two novel triglyceride (TG)-lowering APOC3 RNA inhibitors in these patients. Materials & methods: An individual patient simulation model was developed and implemented using Monte Carlo sampling to assess the impact of novel FCS treatments, plozasiran versus olezarsen, on serum TG levels. Patient-level heterogeneity was captured through a distribution of pre-treatment TG levels matching the PALISADE trial cohort in the base case. Uncertainty in treatment response (percent reduction of TG levels) was modeled using beta distributions with parameters based on the pivotal PALISADE and BALANCE trials for plozasiran and olezarsen, respectively. The proportion of patients who achieved TG levels of <500 mg/dl and absolute TG levels were simulated at different timepoints. Three scenario analyses were conducted to assess the robustness of results to key modeling assumptions: the pre-treatment cohort was matched to the BALANCE trial (scenario 1); the pre-treatment range of TG values was expanded (scenario 2); the pre-treatment cohort was matched to patients with genetically confirmed FCS from the PALISADE trial (scenario 3). Results: In the base case model, simulated patients in the plozasiran group were more likely to achieve TG levels <500 mg/dl at 10 months post-treatment compared with patients treated with olezarsen (56.8% vs 18.2%). A similar pattern was seen across all scenarios and across all time-points evaluated. The microsimulation model was found to be stable with regard to the primary outcome when the number of simulated patients was between 10 and 100,000; results were validated by congruence with reference clinical trial data. Conclusion: This microsimulation model suggests plozasiran’s greater efficacy in TG level reduction, compared with olezarsen, in FCS. Greater reductions in TG levels may reduce exposure to TG concentrations associated with an increased risk of AP.
No takes yet. Share an insight, caveat, or question.
Desai et al. (2026) studied Familial chylomicronemia syndrome (FCS) with severe hypertriglyceridemia. Plozasiran vs. Olezarsen was evaluated on Proportion of patients achieving serum triglyceride levels <500 mg/dl at 10 months post-treatment. Plozasiran resulted in a higher simulated proportion of FCS patients achieving triglyceride levels </dl at 10 months compared with olezarsen.
Synapse has enriched 10 related papers. Consider them for comparative context: